Sumitomo Mitsui Trust Group Inc. Raises Stock Holdings in Masimo Co. (NASDAQ:MASI)

Sumitomo Mitsui Trust Group Inc. raised its position in shares of Masimo Co. (NASDAQ:MASI) by 0.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 373,705 shares of the medical equipment provider’s stock after buying an additional 1,522 shares during the quarter. Sumitomo Mitsui Trust Group Inc. owned about 0.70% of Masimo worth $61,773,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of the business. Blue Trust Inc. lifted its position in Masimo by 56.3% during the 4th quarter. Blue Trust Inc. now owns 197 shares of the medical equipment provider’s stock valued at $33,000 after acquiring an additional 71 shares during the period. NBC Securities Inc. raised its holdings in Masimo by 47.1% in the third quarter. NBC Securities Inc. now owns 228 shares of the medical equipment provider’s stock worth $30,000 after buying an additional 73 shares during the last quarter. MML Investors Services LLC lifted its stake in shares of Masimo by 4.9% in the third quarter. MML Investors Services LLC now owns 2,056 shares of the medical equipment provider’s stock worth $274,000 after buying an additional 96 shares in the last quarter. UMB Bank n.a. grew its holdings in shares of Masimo by 180.9% during the fourth quarter. UMB Bank n.a. now owns 191 shares of the medical equipment provider’s stock valued at $32,000 after buying an additional 123 shares during the last quarter. Finally, Assetmark Inc. increased its position in shares of Masimo by 12.7% during the third quarter. Assetmark Inc. now owns 1,183 shares of the medical equipment provider’s stock valued at $158,000 after acquiring an additional 133 shares in the last quarter. Institutional investors own 85.96% of the company’s stock.

Wall Street Analyst Weigh In

MASI has been the topic of several recent analyst reports. Needham & Company LLC reiterated a “hold” rating on shares of Masimo in a research note on Wednesday, January 22nd. Piper Sandler increased their price objective on Masimo from $180.00 to $210.00 and gave the company an “overweight” rating in a research report on Wednesday, December 18th. Raymond James lifted their price objective on Masimo from $170.00 to $194.00 and gave the stock an “outperform” rating in a report on Friday, December 27th. Wells Fargo & Company upped their target price on shares of Masimo from $171.00 to $193.00 and gave the company an “overweight” rating in a research note on Wednesday, December 11th. Finally, Stifel Nicolaus reissued a “buy” rating and set a $190.00 price objective (up from $170.00) on shares of Masimo in a report on Friday, November 22nd. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $191.40.

Masimo Trading Down 2.1 %

Masimo stock opened at $176.16 on Monday. Masimo Co. has a 52-week low of $101.61 and a 52-week high of $183.14. The company has a market cap of $9.43 billion, a P/E ratio of 121.49 and a beta of 1.02. The company has a quick ratio of 1.11, a current ratio of 2.01 and a debt-to-equity ratio of 0.50. The business has a 50-day simple moving average of $171.63 and a two-hundred day simple moving average of $147.10.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.